CDX2 and gastric cancer: The current study represents, to the best of our knowledge, the first analysis of possible interactions between VSIG1 and MUC2/CDX2, the surrogate markers of intestinal phenotypes of GC, and between VSIG1 and MUC5AC, a surrogate marker of gastric phenotype.